pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

745 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Updated: Allen Institute launches $400M effort to turn brain atlas lessons into medicines
    A Seattle-based nonprofit known for basic brain research is launching a $400 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including Alzheimer'…
    Endpoints · 1mo ago↗ source
  • The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way
    How much is a regulatory shortcut worth? The cost of a priority review voucher, which shortens the FDA’s standard review time by about four months, has roughly doubled in the last few years. The…
    Endpoints · 1mo ago↗ source
  • Epigenetic editing shows promise against chronic hep B infections
    A new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections. Its twist is to silence disease-causing genes without altering the underlying DNA. Tune Thera…
← prev
page 21 of 30
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 1mo ago↗ source
  • Shionogi wins US approval for first pill to prevent Covid following exposure
    Japan's Shionogi on Monday said it won FDA approval for its oral antiviral to prevent Covid‑19 in adults and children older than 12 years who have been in contact with someone ...
    Endpoints · 1mo ago↗ source
  • #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphoma
    Two plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…
    Endpoints · 1mo ago↗ source
  • Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines
    🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib. The South…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update
    CHICAGO — Eli Lilly in April signed an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy ...
    Endpoints · 1mo ago↗ source
  • After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing
    Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. The Monday morning deal comes ...
    Endpoints · 1mo ago↗ source
  • Turn Therapeutics' eczema drug shows rapid response in mid-stage data
    California biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual. In an interim analysis o…
    Endpoints · 1mo ago↗ source
  • Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
    Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that cou…
    Endpoints · 1mo ago↗ source
  • #ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroup
    CHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer. Ind…
    Endpoints · 1mo ago↗ source
  • Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront
    Eli Lilly, which has made billions off the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remain
    CHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday. Treatment…
    Endpoints · 1mo ago↗ source
  • Oculis’ eye drops for diabetic macular edema flunk Phase 3 test
    Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials. After a year, its eye drop called OCS…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that good
    CHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study
    CHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus c…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Personalized cancer vaccines may help brain cancer patients live longer
    Personalized cancer vaccines might make notoriously deadly brain cancers more susceptible to immunotherapy and possibly prolong survival for some patients, according to new research from the Dana-F…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say
    CHICAGO — Grail's blood test, which it has pitched as a way to spot a variety of cancers early in their growth, still isn't ready to be used as a regular screening tool, experts not involved ...
    Endpoints · 1mo ago↗ source
  • Can AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more
    Welcome back to Endpoints Weekly! We’ve got a team of reporters on the ground in Chicago this weekend for ASCO, including my fellow Weekly co-author Max Gelman. If you haven’t already, check out Ma…
    Endpoints · 1mo ago↗ source
  • Next FDA user fee deal is under review at the White House
    The White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the sector will pay the agency from 2028 through 2032, sour…
    Endpoints · 1mo ago↗ source
  • Post-Hoc: Lilly gets more secretive and hides Phase 1 pipeline
    Eli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s earnings pr…
    Endpoints · 1mo ago↗ source
  • AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
    🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…
    Endpoints · 1mo ago↗ source
  • Replimune will again submit its melanoma drug for approval
    Third time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said it has had new discussions with ...
    Endpoints · 1mo ago↗ source
  • Agios ends development of tebapivat in low-risk MDS following subpar results
    Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyr…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successor
    Bristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of a combination treatment regimen. The New Jersey…
    Endpoints · 1mo ago↗ source